目的 探討正心泰顆粒聯(lián)合鹽酸貝尼地平片治療冠心病心絞痛的療效。方法 選取河北港口集團有限公司秦皇島中西醫(yī)結(jié)合醫(yī)院在2024年2月到2025年1月收治的138例冠心病心絞痛患者，按隨機數(shù)字表法將所有患者分為對照組和治療組，各組包括69例。對照組口服鹽酸貝尼地平片，1次/d，2片/次。治療組患者在對照組基礎(chǔ)上沖服正心泰顆粒，3次/d，1袋/次。兩組持續(xù)完成1個月的治療。比較兩組患者的治療效果、心絞痛疼痛程度、心絞痛頻次和持續(xù)時間、生活質(zhì)量、心功能指標、血清指標。結(jié)果 對照組的總有效率為81.16%，治療組的總有效率為92.75%，組間差異顯著（P＜0.05）。兩組治療后的心絞痛頻次、持續(xù)時間、視覺模擬量表（VAS）評分明顯減輕（P＜0.05），且治療組治療后心絞痛頻次、持續(xù)時間、VAS評分均低于對照組（P＜0.05）。治療后，兩組西雅圖心絞痛量表（SAQ）評分均顯著提高（P＜0.05），治療組治療后SAQ評分明顯高于對照組（P＜0.05）。治療后，兩組的左心室射血分數(shù)、短軸縮短率、心輸出量均升高（P＜0.05），且治療組的左心室射血分數(shù)、短軸縮短率、心輸出量比對照組更高（P＜0.05）。兩組患者治療后血清心型脂肪酸結(jié)合蛋白（H-FABP）、T細胞免疫球蛋白黏蛋白分子3（Tim3）、Clq腫瘤壞死因子相關(guān)蛋白1（CTRP1）水平均明顯降低（P＜0.05），治療組治療后血清H-FABP、Tim3、CTRP1水平明顯低于對照組（P＜0.05）。結(jié)論 正心泰顆粒聯(lián)合鹽酸貝尼地平片可提高冠心病心絞痛的療效，減輕心絞痛癥狀，改善生活質(zhì)量，減輕炎癥反應(yīng)，提高心功能。

Objective To explore the therapeutic effect of Zhengxintai Granules combined with Benazepril Hydrochloride Tablets in treatment of angina pectoris in coronary heart disease. Methods 138 Patients with coronary heart disease angina admitted to Hebei Port Group Co., Ltd. Qinhuangdao Integrated Traditional Chinese and Western Medicine Hospital from February 2024 to January 2025 were selected and were divided into control group and treatment group using a random number table method, with 69 cases in each group. The control group of patients took orally Beninidipine Hydrochloride Tablets, 2 tablets each time, once daily. Patients in the treatment group were po administered with Zhengxintai Granules on the basis of the control group, 3 times daily, 1 bag per time. Two groups completed 1 month of treatment continuously. The treatment efficacy, degree of angina pain, frequency and duration of angina, quality of life, cardiac function indicators, and serum indicators were compared between two groups of patients. Results The total effective rate of the control group was 81.16%, while the total effective rate of the treatment group was 92.75%, and the difference between the groups was significant (P < 0.05). The frequency, duration, and visual analog scale (VAS) scores of angina pectoris in both groups were significantly reduced after treatment (P < 0.05), and the frequency, duration, and VAS scores of the treatment group were lower than those of the control group after treatment (P < 0.05). After treatment, the Seattle Angina Questionnaire (SAQ) scores in two groups were significantly increased (P < 0.05), and the SAQ scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, the left ventricular ejection fraction, short axis shortening rate, and cardiac output of two groups were increased (P < 0.05), and the left ventricular ejection fraction, short axis shortening rate, and cardiac output of the treatment group were higher than those of the control group (P < 0.05). After treatment, the serum levels of heart type fatty acid binding protein (H-FABP), T cell immunoglobulin mucin molecule 3 (Tim3), and Clq tumor necrosis factor related protein 1 (CTRP1) in two groups of patients were significantly decreased (P < 0.0), and the serum levels of H-FABP, Tim3, and CTRP1 in the treatment group were significantly lower than those in the control group after treatment (P < 0.05). Conclusion The combination of Zhengxintai Granules and Benazepril Hydrochloride Tablets can improve the efficacy of angina pectoris in coronary heart disease, alleviate angina symptoms, improve quality of life, alleviate inflammatory reactions, and enhance cardiac function.

R972

秦皇島市科學技術(shù)研究與發(fā)展計劃（202301A078）